Endocrine Abstracts (2013) 32 P662 | DOI: 10.1530/endoabs.32.P662

Testosterone undecanoate 1000 mg at 3 months does not increase prostatic specific antigen level: study on over 100 patients, December 2012

Matei Pisoschi1, Daniela Cristina Staicu2 & Dan Peretianu2


1Burghele Hospital, Bucharest, Romania; 2Societatea Civila Medicala ‘Povernei’, Bucharest, Romania.


Aim: To find if testosterone undecanoat 1000 mg injection (Nebido; Bayer-Schering) has a negative effect on prostate.

Materials and methods: i) PSA (ng/ml) was registred retrospective (from files) and prospective analysis (onset 2010). ii) From over 175 patients to whom testosterone undecanoate 1000 mg, i.m. was administrated at 3 months, in the last 4 years, and to whom the prostatic volume was quantified (Journal of Sexual Medicine8 suppl. 7, 2011: PO-05-013), 106 PSA analysis were done before treatment. PSA was recorded (if possible) at T1–T7 (2 weeks–4 years) (see Peretianu, this Congress); at least two analysis were registred. iii) None patient with prostatic cancer was included. iv) Statistical analysis: Student’s t-test, simple correlation, multiple regression.

Results: i) Patients: 106 men, 18–96 years, average: 61.95; median: 62. ii) Prostatic volume (cm3): average: 37.89. iii) Average PSA: i) before treatment: 1.76; ii) post 1 year: 1.9; iii) post 2 years: 1.68; iv) post 3 years: 1.94; v) post 4 years: 2.18.

iv) Statistical difference of average: nonsignificant for all the times from 2 weeks to 4 years. v) Correlation between age and PSA is: i) significant before (r1) and after treatment after 2 years but nonsignificant for 3 and 4 years (PSA did not change as age after treatment). vi) Correlation between PSA and prostatic volume was significant, both before and after treatment.

vii) Multiple regression test (table) shows that PSA level post testosterone does not depend on testosterone but on age, prostatic volume (before and after treatment) and PSA initial level (before testosterone administration).

Table 1 PSA levels in patient treated with testosterone undecanoate 1000 mg at 3 months till 4 years.
T0T1–2 weeksT2–3 monthsT3–6 monthsT3 bis 9 monthsT4–1 yearT5–2 yearsT6 3 yearsT7–4 years
Average1.762.872.452.812.201.901.681.942.18
S.D.1.683.062.543.383.111.781.361.702.20
No10614912108541309
T value vs T00.200.440.310.670.590.760.610.59
Table 2 Correlation age and prostatic volume with PSA in TUD treatment till 4 years.
Correlation age, PSACorrelation prostatic volume, PSA
Before treatmentAt 1 yearAt 2 yearsAt 3 yearsAt 4 yearsBefore treatmentAt 1 yearAt 2 yearsAt 3 yearsAt 4 years
r0.340.330.310.150.070.600.490.550.421.00
P<0.001<0.010.05>0.1>0.1<0.001<0.001<0.001<0.05<0.001
Table 3 Multiple regression test.
ObservationsR2FP
1 year TUD700.5224.03<0.001
After 2 years TUD380.7534.28<0.001
After 3 years TUD200.8947.84<0.001
After 4 years TUD80.836.50.0509

Conclusions: i) Testosterone undecanoat 1000 mg injectable i.m. at 3 months does not increase significantly PSA level after 4 years administrations. ii) PSA level post testosterone is in fact dependent on age, prostatic volume before treatment and the level before treatment.

Article tools

My recent searches

No recent searches.